Generic Name: daunorubicin and cytarabine
Brand Name: Vyxeos
Manufacturer: Jazz Pharmaceuticals Canada Inc.
Therapeutic Area: Acute myeloid leukemia
Indications: For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Manufacturer Requested Reimbursement Criteria1: For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Submission Type: Initial
Tumour Type: Leukemia
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||December 17, 2020|
|Call for patient/clinician input closed||February 12, 2021|
- Patient input submission received from The Leukemia & Lymphoma Society of Canada
|Submission received||January 22, 2021|
|Submission accepted||February 05, 2021|
|Review initiated||February 08, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||April 23, 2021|
|Deadline for sponsors comments||May 04, 2021|
|CADTH responses on draft review report(s) provided to sponsor||May 31, 2021|
|Expert committee meeting (initial)||June 10, 2021|
|Draft recommendation issued to sponsor||June 22, 2021|
June 24, 2021
|Draft recommendation posted for stakeholder feedback||-|